Modality
Nanobody
MOA
PD-L1i
Target
PLK4
Pathway
Innate Imm
ALLLGS
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Jul 2030
Phase 2Current
NCT08935550
2,632 pts·ALL
2022-07→2030-07·Completed
NCT05386354
301 pts·LGS
2025-09→TBD·Terminated
2,933 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-234.3y awayPh3 Readout· ALL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2030-07-23 · 4.3y away
ALL
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08935550 | Phase 2/3 | ALL | Completed | 2632 | FEV1 |
| NCT05386354 | Phase 2/3 | LGS | Terminated | 301 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 |